Margo Roberts
Director/Board Member at UNITY BIOTECHNOLOGY, INC.
Net worth: - $ as of 29/04/2024
Profile
Margo R.
Roberts is an Independent Director at Unity Biotechnology, Inc. since 2018 and a Director at Appia Bio, Inc. since 2022.
Previously, she served as the Director-Immune & Cell Therapy at Cell Genesys, Inc. from 1990 to 1998.
She was also an Independent Director at Celyad Oncology SA from 2018 to 2020.
Dr. Roberts held the position of Associate Professor at the University of Virginia from 1999 to 2011.
She was the Chief Scientific Officer & SVP-Discovery Research at Kite Pharma, Inc. from 2011 to 2018 and the Chief Scientific Officer at Lyell Immunopharma, Inc. from 2019 to 2021.
Dr. Roberts has a background in undergraduate and doctorate studies from the University of Leeds.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
22/04/2024 | 0 ( -.--% ) | - $ | 29/04/2024 |
Margo Roberts active positions
Companies | Position | Start |
---|---|---|
UNITY BIOTECHNOLOGY, INC. | Director/Board Member | 03/12/2018 |
Appia Bio, Inc.
Appia Bio, Inc. BiotechnologyHealth Technology Appia Bio, Inc. is an early stage biotechnology company based in an undisclosed location. Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. The American company utilizes the biology of lymphocyte development with chimeric antigen receptor (CAR) and T cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-NKT) or gamma delta T cells from hematopoietic stem cells (HSCs) with its ACUA (Appia Cells Utilized for Allogeneic) technology platform. The ACUA platform was developed from groundbreaking research in the laboratory of Lili Yang, Ph.D., at the University of California, and collaboration with Appia Bio's other scientific founders, David Baltimore, Ph.D. at Caltech and Pin Wang, Ph.D. at the University of Southern California. The company was founded in 2020 by Jeffrey S. Wiezorek, David Baltimore, Jeenjoo Kang, Lili Yang, Edmund Kim, and Pin Wang. Jeenjoo Kang has been the CEO since 2020. | Director/Board Member | 08/08/2022 |
Former positions of Margo Roberts
Companies | Position | End |
---|---|---|
LYELL IMMUNOPHARMA, INC. | Chief Tech/Sci/R&D Officer | 31/12/2020 |
CELYAD ONCOLOGY SA | Director/Board Member | 05/08/2020 |
KITE PHARMA INC | Chief Tech/Sci/R&D Officer | 30/06/2018 |
University of Virginia | Corporate Officer/Principal | 30/11/2011 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Corporate Officer/Principal | 30/11/1998 |
Training of Margo Roberts
University of Leeds | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 4 |
---|---|
CELYAD ONCOLOGY SA | Health Technology |
UNITY BIOTECHNOLOGY, INC. | Health Technology |
LYELL IMMUNOPHARMA, INC. | Health Technology |
INSTIL BIO, INC. | Health Technology |
Private companies | 3 |
---|---|
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Health Technology |
Kite Pharma, Inc.
Kite Pharma, Inc. BiotechnologyHealth Technology Kite Pharma, Inc. engages in the the development and commercialization of cancer immunotherapy products. Its products include chimeric antigen receptor (CAR) and T cell receptor (TCR), which address both hematological and solid cancers. The company was founded by Arie S. Belldegrun, James S. Economou, and Joshua A. Kazam on 2009 and is headquartered in Santa Monica, CA. | Health Technology |
Appia Bio, Inc.
Appia Bio, Inc. BiotechnologyHealth Technology Appia Bio, Inc. is an early stage biotechnology company based in an undisclosed location. Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. The American company utilizes the biology of lymphocyte development with chimeric antigen receptor (CAR) and T cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-NKT) or gamma delta T cells from hematopoietic stem cells (HSCs) with its ACUA (Appia Cells Utilized for Allogeneic) technology platform. The ACUA platform was developed from groundbreaking research in the laboratory of Lili Yang, Ph.D., at the University of California, and collaboration with Appia Bio's other scientific founders, David Baltimore, Ph.D. at Caltech and Pin Wang, Ph.D. at the University of Southern California. The company was founded in 2020 by Jeffrey S. Wiezorek, David Baltimore, Jeenjoo Kang, Lili Yang, Edmund Kim, and Pin Wang. Jeenjoo Kang has been the CEO since 2020. | Health Technology |
- Stock Market
- Insiders
- Margo Roberts